Scarica l'app Stockscreener
25.70
1.98%
-0.52
Dopo l'orario di chiusura:
25.70
Alto Neuroscience Inc Borsa (ANRO) Ultime notizie
Alto Neuroscience (ANRO) Edges Lower as Shares Test Key Support ZoneEquity Put Call - dars.gov.et
ANROAlto Neuroscience Inc Latest SEC Filings - Finviz
Price to earnings forward of Alto Neuroscience, Inc. – NYSE:ANRO - TradingView
Alto Neuroscience Announces Participation in Upcoming Investor Conferences - The National Law Review
Is Alto Neuroscience, Inc. (ANRO) Stock Positioned for Growth With New Insights Into Anhedonia Treatment? - Yahoo Finance
ANRO Stock Falls After Hours On Failed Schizophrenia Study Results - Stocktwits
5 Best Up and Coming Pharmaceutical Stocks to Buy Now - Insider Monkey
Alto Neuroscience, Inc.(NYSE: ANRO) added to Russell 2000 Index - marketscreener.com
Alto Neuroscience, Inc.(NYSE: ANRO) added to Russell 2500 Growth Benchmark - marketscreener.com
Alto Neuroscience Inc. (ANRO) Q1 2026 Earnings: Wider Loss Per Share on Higher R&D SpendingLow Estimate Range - dars.gov.et
Alto Neuroscience, Inc.(NYSE:ANRO) dropped from Russell Microcap Value Benchmark Index - marketscreener.com
Alto Neuroscience, Inc.(NYSE: ANRO) added to Russell Microcap Growth Benchmark Index - marketscreener.com
Alto Neuroscience, Inc.(NYSE: ANRO) added to Russell 2000 Growth Benchmark - marketscreener.com
Alto Neuroscience, Inc.(NYSE: ANRO) added to Russell 3000E Growth Benchmark - marketscreener.com
Levi & Korsinsky Notifies Alto Neuroscience, Inc. (ANRO) Sharehol - The National Law Review
Investors SueWallSt as Alto Neuroscience, Inc. Faces Securities Fraud Allegations - The National Law Review
ANRO INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announc - The National Law Review
ANRO Investors Have Opportunity to Lead Alto Neuroscience, Inc. C - The National Law Review
ANRO INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds - The National Law Review
Alto Neuroscience, Inc. (ANRO) Class Action Lawsuit: Levi & Korsi - The National Law Review
H.C. Wainwright Remains a Buy on Alto Neuroscience, Inc. (ANRO) - The Globe and Mail
Alto Neuroscience, Inc. Actuals & Estimates (BOATS:ANRO) - TradingView
H.C. Wainwright Maintains Alto Neuroscience(ANRO.US) With Buy Rating, Maintains Target Price $50 - Moomoo
Alto Neuroscience Inc (ANRO) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
ANRO Stock Drops 7% After Disappointing Schizophrenia Study Results – But Analyst Sees Dip As Attractive Entry Point - Stocktwits
Alto Neuroscience Inc (ANRO) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Top Alto Neuroscience (ANRO) Competitors 2026 - MarketBeat
Alto Neuroscience Inc (ANRO) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Alto Neuroscience Inc (ANRO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Alto Neuroscience Inc (ANRO) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Alto Neuroscience Inc (ANRO) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Alto Neuroscience Inc (ANRO) Valuation: PE, PB & Fair Value Analysis - TradingKey
Alto Neuroscience Inc (ANRO) Institutional Confidence - TradingKey
Alto Neuroscience Inc (ANRO) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
ANRO Q1 2026 Earnings: Wider-Than-Expected Loss Per Share Amid Clinical ProgressEarnings Analysis - dars.gov.et
Alto Neuroscience Highlights Nature Medicine Publication Demonstrating Significant Effects of Pramipexole on Anhedonia - Weekly Voice
Alto Neuroscience Inc. (ANRO) Q1 2026 Earnings: Wider-than-Expected Loss as Clinical-Stage Biotech Advances PipelineRevenue Beat Analysis - newsline.com
ANRO Q1 2026 Earnings: Wider-than-Expected Loss Weighs on Investor SentimentEarnings Cycle Outlook - newsline.com
ANRO: Three late-stage psychiatry programs expect pivotal data readouts in 2027 - TradingView
Alto Neuroscience (ANRO) Jefferies Global Healthcare Conference 2026 Summary - Quartr
Alto Neuroscience (ANRO) Edges Lower as Stock Hovers Near Key Support ZoneIndex Put Call - The Legal Advocate
Alto Neuroscience (ANRO) director awarded 26,000 stock options at $20.44 strike price - Stock Titan
Alto Neuroscience (ANRO) director Andrew Craig Miller files initial Form 3 - Stock Titan
Alto Neuroscience Appoints Karuna Therapeutics Founder Andrew Miller to Board of Directors - geneonline.com
Alto Neuroscience, Inc. (ANRO) Files 8-K Report Announcing No Soliciting Material or Tender Offers – Company Info & NYSE Listing - Minichart
Alto Neuroscience appoints Andrew Miller to board of directors By Investing.com - Investing.com South Africa
Alto Neuroscience appoints Andrew Miller to board of directors - Investing.com
Biotech leader Andrew Miller joins Alto Neuroscience (ANRO) board and governance committee - Stock Titan
Alto Neuroscience Appoints Karuna Therapeutics Founder Andrew Miller, Ph.D. to Board of Directors - Business Wire
H.C. Wainwright reiterates Alto Neuroscience stock rating at buy - Investing.com UK
H.C. Wainwright reiterates Alto Neuroscience stock rating at buy By Investing.com - Investing.com Australia
Wolfe Research initiates Alto Neuroscience stock with outperform rating - Investing.com India
ANRO Q1 2026 Earnings: EPS Misses Estimates as Pre-Revenue Biotech Advances PipelineEBITDA Estimate Trend - newsline.com
Alto Neuroscience Analyst Ratings and Price Targets | NYSE:ANRO - Benzinga
1.17%
2.48%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):